Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

NCT05460000 is registered in ClinicalTrials.gov with North Eastern German Society of Gynaecological Oncology as lead sponsor.

NCT NCT05460000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05460000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
October 11, 2024
Completion date
October 1, 2032
Enrollment
640 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell carcinoma, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma